Our lecturers are actively involved in the different phases of translation including basic research, preclinical studies, and clinical studies. You profit from both the practical experience and theoretical background of lecturers working in academia, industry and regulatory agencies. Get to know these key opinion leaders and expand your professional network.
Barkow, Tom; MDSS
Batkai, Sandor Dr.; MHH
Baumann, Knut Prof. Dr.; TU Braunschweig
Blasczyk, Rainer Prof. Dr.; MHH
Bock von Wülfingen, Christiane; MHH
Braun, Armin Prof. Dr.; Fraunhofer ITEM
Brönstrup, Mark Prof. Dr.; Helmholtz-Zentrum für Infektionsforschung
Bunjes, Heike Prof. Dr.; TU Braunschweig
Cordes, Ralf Dr.; Ascenion GmbH
Döhler, Klaus Prof. Dr.; Curatis Pharma GmbH
Doll, Theodor Prof. Dr.; MHH
Gerdelmann, Jens Dr.; MDSS
Grode, Leander Dr.; Vakzine Projekt Management GmbH (VPM)
Harder, Michael Dr.; corlife oHG
Haverich, Axel Prof. Dr.; MHH
Hesterkamp, Thomas Dr.; Deutsches Zentrum für Infektionsforschung
Hoffmann, Christine Dr.; TU Braunschweig
Jäger, Cornelius; MHH
Kalesse, Markus Prof. Dr.; Leibniz Universität Hannover
Kalinke, Ulrich Prof. Dr.; TWINCORE
Kielhorn-Schönermark, Heike; SKC Beratungsgesellschaft mbH
Klöß, Stephan Dr.; MHH
Köhl, Ulrike Prof. Dr.; MHH
Kunick, Conrad Prof. Dr.; TU Braunschweig
Kwade, Arno Prof. Dr.; TU Braunschweig
Mertz, Marcel; MHH
Meier, Martin Dr.; MHH
Mittelmaier, Roland; Reet – Unternehmen entwickeln
Möller, Ludger Dip.-Ing.; Medical Device Safety Service Hannover
Müller-Berghaus, Jan Dr.; Paul Ehrlich Institut
Müller-Goymann, Christel Prof. Dr.; TU Braunschweig
Oberschmidt, Olaf, Dr.; MHH
Ott, Ingo Prof. Dr.; TU Braunschweig
Reichl, Stephan PD Dr.; TU Braunschweig
Reinhardt, Jens Dr.; PEI Langen
Salmon, Rene; hannoverimpuls;
Schambach, Axel Prof. Dr.; MHH
Schilling, Tobias Dr.; MHH
Schindler, Christoph Prof. Dr.; MHH Core Facility
Schneider, Christian Dr.; National Institute for Biological Standards and Control (NIBSC)
Schwarz, Katharina Dr.; Fraunhofer ITEM
Schönermark, Matthias P. Univ.-Prof. Dr. med.; SKC Beratungsgesellschaft mbH
Seltsam, Axel Prof. Dr.; DRK Blutspendedienst NSTOB
Sewald, Katherina Dr.; Fraunhofer ITEM
Stadler, Marc Prof. Dr.; HZI
Stichtenoth, Dirk Prof. Dr.; MHH
Strätz, Michael Dr.; HZI
Stripecke, Renata Prof. Dr.; MHH
Taruttis, Stefan Dr.; Taruttis Patentanwaltskanzlei
Thiele, Susanne; HZI
Voigt, Henning Dr.; MHH
Vorwachs, Viktoria; hannoverimpuls
Ziehr, Holger Dr.; Fraunhofer ITEM
Sandor Batkai is a medical researcher specialized in the cardiovascular field and currently holds the position of group leader of Cardiovascular Phenotyping and Translational Strategies at the Hannover Medical School. He previously headed the Cardiovalscular Phenotyping Core facility at the US National Institutes of Health (NIH), where his work also required direct interaction with regulatory authorities. He is an established scientist in cardiovascular research and pharmacology with over 100 publications in high ranking scientific journals. He is an expert in oligonucleotides pharmacology, biomarker development and experienced in industry sponsored drug development collaborations. His recent focus is on translational non-coding RNA research and development of microRNA therapeutics in heart failure.
Prof. Dr. Knut Baumann is Professor of Medicinal Chemistry at the University of Technology Braunschweig, Germany. He received his PhD from the Julius Maximilian University of Würzburg, Germany, and started his academic career at the University of Berne, Switzerland. His research focusses on chemoinformatics and chemometrics.
Rainer Blasczyk is a full professor and chair of the Department for Transfusion Medicine at Hannover Medical School (MHH) since 1998. Rainer Blasczyk studied medicine at the Universities of Essen and Bochum where he received his Dr. med. After a clinical education in abdominal surgery at the University of Marburg, hematology and oncology at the University of Düsseldorf and transplantation immunology at the University of Essen he finished his medical specialization in transfusion medicine at the Humboldt-University of Berlin. His work focuses on structural, functional and clinical research of the human MHC for allogeneic, adoptive and regenerative cell therapy including genetic engineering of primary cells and stem cells to decrease their immunogenicity. His translational work aims at improving molecular diagnostics, cellular immunotherapy, as well as stem cell, tissue and organ transplantation.
Christiane Bock von Wülfingen has a diploma in social sciences from the University of Hannover with a focus on health politics, law and social psychology. Before and during her studies she worked as an intensive care nurse at Hannover Medical School. She completed consecutive studies in Media: Production, Projects and Public Relations (Hannover/Berlin) and has many years of experience in the fields of consulting, creating advanced training concepts, project management, law, leadership and management. Between 2009 and 2014 she led the “MHHpersonalAkademie”. Since 2015 she is head of the core area research and education, conception of career and advanced training for scientists and physicians of the newly founded “MHH Weiterbildungsakademie” (WBA).
Prof. Armin Braun is Division Director of the Preclinical Pharmacology and In Vitro Toxicology of the Fraunhofer Institute for Toxicology and Experimental Medicine. His main focus is the preclinical development and evaluation of new drugs for airway diseases. Clients are the major pharmaceutical and biotech companies from Europe, US and Japan. Therefore he has extensive experience with animal models of lung disease like asthma, COPD of lung infection. In addition, immunotoxicology is an important field of work. Based on these knowledge alternative in vitro models are developed e.g. using precision cut lung slice (PCLS) technique for testing lung toxicology and immune regulation. Immunological diagnosis in clinical studies is performed by immunohistological staining techniques using confocal microscopy, flow cytometric analysis and biomarker quantification in bronchoalveolar lavage fluid and blood. His work is funded by different EU and federal research agencies. He is member of the German center of lung research (DZL) and was active in the collaborative research network SFB587 “Immune reactions of the lung in infection and allergy” where the interaction of nervous system and immune reactions in asthma was the focus of research. Prof. Braun has a strong background in basic research and is involved in several public funded research collaborations e.g. with the Medical School Hannover (MHH) where he is acting as a Professor. International collaborations include vaccine development together with the Fraunhofer CMB in the US. He has published more than 100 reports in international journals.
Mark Brönstrup studied chemistry and obtained his PhD from the TU Berlin in 1999. He joined Aventis in 2000 as a lab head for mass spectrometry and spent a research sabbatical with S. P. Gygi at Harvard Medical School in 2003. Between 2005 and 2010, he was leading the Natural Products Science section at Sanofi Aventis in Frankfurt. Between 2010 and 2013, he was managing sections dealing with biomarkers, bioimaging & biological assays. Since December 2013, he has been head of the Chemical Biology Department at the Helmholtz Centre for Infection Research in Braunschweig and W3 Professor at the University of Hannover. His research is focused on the discovery, the characterization and the optimization of novel antiinfective drugs.
Heike Bunjes studied Pharmacy in Braunschweig and received her PhD in Pharmaceutics from the University of Jena in 1998. Since 2007 she is professor for Pharmaceutical Technology at the Technische Universität Braunschweig. Her research is mainly concerned with the formulation of poorly water soluble drug substances by employing nanoparticulate and nanostructured delivery systems. She is a co-founder and board member of the Center of Pharmaceutical Engineering (Zentrum für Pharmaverfahrenstechnik – PVZ), a research center of the TU Braunschweig.
From 1997-2002 he was Medical Director and Head of Medical Marketing of Region 6 in Solvay Pharmaceuticals GmbH, Hannover. Region 6 comprised Canada, Asia, the Middle East, India, Australia, and South Africa. Bernd was responsible for the planning and conduct of local and region-wide marketing campaigns for Solvay’s influenca vaccine and for its cardiovascular, gastroenterology, gynecology, and psychiatry products. Additionally, Bernd planned and supervised the company’s pivotal trials within the Region which were needed for local registrations (e.g., for PR China). In 2002, he was appointed Global Product Director for psychiatry and became responsible for the world-wide marketing of Solvay Pharmaceuticals’ psychiatry products. Bernd had joined Solvay in 1996 and was responsible for the international phase III development program of one of Solvay´s leading cardiovascular products. Bernd Eisele began his career in the industry as a Clinical Project Manager at Behringwerke AG in 1988. In various positions Bernd was responsible for the clinical development of recombinant and transgenic products in clinical phases I – III. Bernd Eisele holds a doctorate in medicine from Heidelberg Medical University (1986). Bernd Eisele M.D. is CEO of Vakzine Projekt Management GmbH since 2008.
Britta Eiz-Vesper is the leader of the Research and Development department of the Institute for Transfusion Medicine and leader of the group “Molecular Immunotherapy”. She studied biology at the Ernst-Moritz-Arndt University in Greifswald and received her PhD in 1996 in the Institute for Virology at Hannover Medical School. Scine 1999 she worked at the Institute for Transfusion Medicine with a strong focus in the establishment of allogeneic cell-based therapies. In 2007 she finished her habilitation in Molecular Immunotherapy and became W2 professor in 2009. In 2012 she and her group established the worldwide first allogeneic T-cell donor registry alloCELL (www.allocell.org) for the purpose of identifying suitable T cells donors, providing personalized antiviral T-cell immunotherapeutics to patients in need, and monitoring programs for pathogen-specific T cells in patients after transplantation. Britta Eiz-Vesper is one of the Qualified Persons in the Institue and expert in clinical-scale T cell production and GMP T cell engineering technology. The manufacturing license was obtained for generating clinical-grade CMV-, ADV-, EBV- and multivirus-specific T-cell products as advanced therapy medicinal product (ATMP) according to the German Medicines Act (AMG) and clinical-grade antiviral T cells were generated from family and alloCELL donors.
Constança Figueiredo is leader of the group “Cell Therapy” at the Institute for Transfusion Medicine and the Excellence Cluster REBIRTH. She studied Biology at the University of Coimbra, Portugal. After engaging a PhD program in Experimental Biology and Biomedicine, Constança Figueiredo joined the Institute for Transfusion Medicine at the Hannover Medical School (Prof. Dr. Rainer Blasczyk). In 2006, she graduated with a PhD in Cell Biology and Immunology. Since 2008, she is group leader with major interests in blood pharming (large-scale in vitro production of blood cell components) and the reduction of immunogenicity of allogeneic cell-based products to prevent rejection after transplantation. In 2014, she received the “Venia Legendi” for Experimental Transfusion Medicine. Figueiredo’s group developed an innovative strategy to prevent a humoral and cellular-mediated allogeneic rejection of donated or in vitro pharmed cell products used for regenerative therapeutic purposes. Silencing HLA expression in transplants generates a condition of immunological invisibility allowing their application in an universal manner independently of the donor and recipient’s major and minor histocompatibility profile and may overcome the need of immunosuppression. HLA-universal cell products may become the “next generation” transplants in regenerative medicine.
Ilona Fleischhauer studied chemistry at the Ruhr-University in Bochum / Germany. Her doctoral thesis dealt with research in organic chemistry. During her studies she was a fellow of “Studienstiftung des deutschen Volkes”. Afterwards she did postdoctoral research at the University of California, Berkeley / USA, supported by a Feodor-Lynen fellowship of the Humboldt Foundation. Ilona Fleischhauer started her professional career as lab manager (pharmaceutical development, chemical synthesis) in a research-oriented pharmaceutical company in Frankfurt / Germany. After 10 years she switched to quality assurance leading a group focused on GLP (Good Laboratory Practice) and GCP (Good Clinical Practice). Since 2004, she has worked at the Fraunhofer Institute for Toxicology and Experimental Medicine in Hannover / Germany. As Head of Quality Assurance she has been responsible for further developing the GLP quality assurance programme and for setting up the GCP quality assurance programme which was also important for the recently established „Clinical Research Center Hannover“. In addition, for several years she has been active as a quality assurance consultant for other GLP test facilities and has given GLP trainings for various sponsors.
Since 2009 Dr. Jens Gerdelmann is working in the area of regulatory affairs and quality management for medical devices. First for the MDSS GmbH and since 2014 for the split off MDSS Consulting GmbH. Prior to this Dr. Gerdelmann worked, after completing his studies of biology, for nearly ten years as postgraduate and post-doc in scientific research at medical and biophysical university institutes. After completing diverse seminars and workshops in regulatory affairs and quality management Dr. Gerdelmann holds certificates as quality manager and auditor. Dr. Gerdelmann is working as safety officer for medical devices and as consultant for medical devices including IVD.
Dr. Gerdelmann’s consulting activity includes assistance with submission of applications for approval and evaluation of medical device clinical investigations as well as reporting of serious adverse events in clinical investigations. In addition Dr. Gerdelmann is author of clinical evaluation reports for medical device manufacturers.
Thomas Hesterkamp studied Human Biology at Marburg and Heidelberg Universities and obtained his PhD in 1997. His first professional job was at Arpida AG in Switzerland where he was involved in Research and Development of novel antibacterial compounds. From 2000 to 2013 Thomas held various scientific and managerial positions at Evotec AG in Hamburg. Amongst others he participated in major research collaborations with Ono Pharmaceutical, Cubist Pharmaceuticals, Bayer, Genentech and later major US universities and research institutions. Since 2013 Thomas is heading the Office for Translational Project Management (TPMO) of the German Center for Infection Research (DZIF).
Christine Hoffmann studied pharmacy in Braunschweig and is a certified pharmacist since 2000. After receiving her doctorate in pharmaceutical technology with a focus on "permeation of drugs from dermal preparations by organotypic skin models" in 2006, she is active as an academic councilor in several fields, including the education of students. She specializes in the field of drug morphology, biopharmaceutics and quality assurance in the manufacturing and testing of medicinal products and medical devices.
Ulrich Kalinke studied biology in Hannover and received his doctorate at the German Cancer Research Center (DKFZ) in Heidelberg. There he investigated the role of CD8 as a co-receptor in the specific T cell recognition and aspects of peripheral T cell tolerance. During a postdoctoral and research assistant phase and at the University Hospital of Zurich, he worked in the laboratory of Nobel laureate Rolf Zinkernagel. There he focused on the analysis of virus-neutralizing antibody responses. After that, he did research as a staff scientist and head of the Anti-Viral Defense Group at the European Molecular Biology Laboratory (EMBL) in Monterotondo near Rome (Italy) for four years. Subsequently, he was appointed as Director and Professor of the Department of Immunology at the Paul-Ehrlich-Institute in Langen. There he was responsible for all aspects of the approval of monoclonal and polyclonal antibodies and therapeutic vaccines. He also examined the interface between innate and adaptive antiviral immunity as well as regulatory research topics such as challenges and opportunities of monoclonal antibodies and the development of therapeutic tumor vaccines. Currently Prof. Kalinke is Managing Director of the TWINCORE and as Professor of Translational Infection Research at the MHH director of the Institute for Experimental Infection Research. In addition to conducting translational research projects, he contributes to the development of new teaching formats on regulatory issues that are relevant in the conduct of clinical trials. In his own group, he is currently investigating antiviral immunity and viral immune evasion. Another focal point is the analysis of virus control within the central nervous system. The goal is to develop new therapeutic and preventive antiviral strategies. In addition, Prof. Kalinke is site manager of the translational alliance in Lower Saxony (TRAIN).
Heike Kielhorn-Schönermark studied business administration in Bayreuth. Before and throughout her studies, she worked as a trainee and later as an industrial clerk at the Siemens AG headquarter and at KPMG, among other places in Munich, Berlin and New York.
After graduating she entered the field of economic auditing and corporate financial consulting at KPMG in Munich. Later on, she also worked in Hamburg. After working for HypoConsult in the area of transactional M&A consulting for a while, she joined the international strategy consulting firm The Boston Consulting Group in 1999. During this time she worked in Hamburg, Amsterdam, Paris and London. In her subsequent position as the Director of Corporate Development of a medium-sized stock company in the biotechnology industry she gained extensive knowledge about medicine startup companies. Heike Kielhorn founded SKC consulting together with Professor Matthias Schönermark in 2005. She has been managing partner since then.
Dr. Stephan Klöß, PhD, is an immunologist and as a senior scientist responsible for quality control in the GMP Development Unit of the Institute of Cellular Therapeutics at the Hannover Medical School, Germany. He studied biology/biochemistry, received his PhD in 2001 and continued his scientific research work at the cardiovascular physiology and Pediatric Hematology and Oncology (Laboratory of Stem Cell Transplantation and Immunotherapy) in the hospital of the Frankfurt University, Germany. Acting in cooperation with Prof. U. Köhl, he moved in July 2012 to the Hannover Medical School for increasing his activities in cell-based therapies among the Integrated Research and Treatment Center Transplantation (IFB-Tx, Ref.No.01E00802) financed by the German Federal Ministry of Education and Research. He is an experienced and competent person in training Ph.D. and M.D. students as well as in teaching hematology/oncology and immunology lectures and doing exams for postgraduate and undergraduate students. Currently he is going to finish his postdoctoral lecture qualification.
Ulrike Köhl is an immunologist and director of the Institute of Cellular Therapeutics at the MHH. She studied both, biology and medicine, received her PhD in 1995 and continued her scientific work at the MD Anderson Cancer Centre in Houston, USA. In 2000 she became the head of the laboratory of stem cell transplantation and immunotherapy in the Paediatric Haematology and Oncology at the University Hospital, Frankfurt, Germany. In 2008 she finished her habilitation in medicine and immunology and received lecturer’s qualification. Since May 2012 she started with a full professorship for Cellular Therapeutics in the Integrated Research and Treatment Centre for Transplantation (IFB-Tx), leading the GMP Development Unit (GMPDU) and the Cellular Therapy Centre (CTC), being one of the Qualified Persons in the latter one. All her goals have a clinical focus on the development and manufacturing of cell-based therapies including Advanced Therapy Medicinal Products (ATMPs) and the improvement of cell processing strategies. One further, but closely related focus of her work includes flow-cytometric quality control for Somatic Cell Therapy as well as Gene Therapy products, the determination of functional capability and multivariate immune reconstitution models to optimize the time points for cell-based therapies. She is a member of numerous national and international societies and is serving as a reviewer for the European Medicine Agency.
After receiving a doctorate degree in Pharmaceutical Chemistry at the Universität Hamburg, Conrad Kunick worked from 1988-1991 as postdoc at the Universität Bonn. He subsequently returned to Hamburg as research fellow, where he focused his scientific interest in the design and synthesis of novel antiproliferative agents. In 2003 he was appointed Professor in Pharmaceutical Chemistry at the Technische Universität Braunschweig. His current scientific projects are directed toward design, synthesis and structure-activity relationships of protein kinase inhibitors with applications as antiinfective and anticancer agents. The commercially most successful compounds from his lab are the paullones, a class of standard protein kinase inhibitors which are offered for sale by more than 30 commercial vendors.
Peter Lotz studied law in Frankfurt/Main and in New York. He holds a Master of Comparative Jurisprudence from New York University School of Law and is admitted to the bar in Germany and in the State of New York. He has counseled multinational as well as medium-sized enterprises for more than 15 years in the areas of life sciences and technology, including 10 years with one of the largest international law firms in their offices in Frankfurt/Main, Chicago and Munich. In particular, he advises technology companies in connection with the cross-border acquisition, licensing, and commercialization of novel technologies, the structuring of international research and development collaborations as well as on regulatory issues in connection with the development of therapeutic and diagnostic products.
Marcel Mertz has studied philosophy and sociology at the University of Basel and gained his PhD in philosophy at the University of Mannheim. Besides working for the Hannover Medical School since 2011, he worked at the University of Basel (Department Medical and Health Ethics), the University of Mannheim (Philosophical Seminar) and the University of Cologne (Research Unit Ethics / Cologne Center for Ethics, Rights, Economics and Social Sciences of Health (ceres)), mainly in interdisciplinary medical and research ethics. His focal research interests are the methodology of medical ethics, esp. empirical ethics, systematic reviews and evaluation methods in health technology assessment. In research ethics, his work focuses on risk-benefit-assessment and uncertainty as well as on the professional ethos in research settings. Furthermore, he has done research in clinical ethics, i.a. on clinical ethics consultation approaches and particularly on ethics guideline development. Also, he researched inter- and transdisciplinarity of medical ethics.
Mertz coordinates currently the working group “Ethik und Empirie (“Ethics and Empiricism”) of the German Akademie für Ethik in der Medizin (“Academy for Ethics in Medicine”).
Christel Müller-Goymann graduated in Pharmacy from TU Braunschweig, received PhD and Habilitation in Pharmaceutical Technology from the same university and was appointed full professor at the Institute of Pharmaceutical Technology of Philipps-University Marburg in 1989 before accepting a full professorship at TU Braunschweig in 1991, where she remains the head of the Institute of Pharmaceutical Technology. She is a co-founder and board member of the Center of Pharmaceutical Engineering (Zentrum für Pharmaverfahrens-technik – PVZ), a research center of the TU Braunschweig. She also serves as a chair of an expert group of the European Pharmacopoeia in Strasbourg. Her research focuses on the development and bio-pharmaceutical evaluation of colloidal drug delivery systems mainly for dermal and mucosal administration.
Ingo Ott studied Pharmacy at the University of Innsbruck and received a pharmacists license (“Approbation”) in Austria. He obtained the PhD degree (Dr. rer. nat.) at the Institute of Pharmacy at Freie Universität Berlin and performed postdoctoral studies in the same institute as well as in the Key Laboratory of Chemical Biology at East China University of Science and Technology in Shanghai. In 2009 Ingo Ott was appointed Professor for Medicinal and Pharmaceutical Chemistry at Technische Universität Braunschweig. His research interests are focused on Medicinal Inorganic Chemistry, Bioorganometallic Chemistry and the biomedical properties of transition metal complexes in general. The results are documented in more than 100 peer-reviewed papers, reviews and patents. In 2011 he received the Innovation Award in Medicinal / Pharmaceutical Chemistry by the German Chemical and Pharmaceutical Societies (GDCh and DPhG).
Christoph Priesner studied biology at the University of Bielefeld und graduated at its Technical Faculty on industrial up- und downstream processing of monoclonal antibodies. He started his career at the Helmholtz Centre for Infection Research in Braunschweig where he worked on proteomics of primary murine cells and cell lines. In 2005 Christoph Priesner changed to a biotech company in Hannover as a team leader and later Head of Quality Control and Qualified Person, involved in the development and manufacture of medicinal standard products as well as of advanced therapy investigational medicinal products (ATIMP), both derived from human tissue and blood. Since 2011 he belongs to the Cellular Therapy Centre of the then newly founded Institute of Cellular Therapeutics of Hannover Medical School (MHH) where he currently works as a Qualified Person and Quality Manager for a comparable variety of medicinal products for human use. With his exceeding 20 years of expertise in human and animal cell culture and processing and more than 10 years of experience in regulatory affairs – not limited to cellular therapeutics –, Christoph Priesner also provides transdisciplinary consultation for MHH’s and external organisations in the fields of Good Manufacturing, Professional, and Clinical Practice (GMP, GFP, GCP).
Dr. Carmen Puschmann has been working at corlife oHG since 2006. Corlife is a developer and manufacturer of medicinal products (tissue preparations) and medical devices for cardiovascular surgery (www.corlife.eu). After studying biology at the Leibniz University of Hanover, she received a doctor’s degree in the field of cell biology on the topic of “Tissue Engineering of valve bearing venous segments in an allogeneic ovine model”. In 2002, she transferred this project from Leibniz Research Laboratories for Biotechnology and Artificial Organs (www.LEBAO.de) into the biotech company ARTISS GmbH to standardize the procedures as a project manager. Since founding of corlife in 2006 Carmen Puschmann has been active in the field of development and regulatory affairs of medical devices.
Stephan Reichl studied Pharmacy in Braunschweig and received his PhD in 2003 and Habilitation in Pharmaceutical Technology and Biopharmaceutics from the TU Braunschweig in 2013. Currently, he is group leader at the Institute of Pharmaceutical Technology in Braunschweig and visiting professor for Pharmaceutical Technology and Biopharmaceutics at the University of Hamburg. His research focuses on cell based in-vitro models of epithelial and endothelial barriers for drug transport studies, new excipients for the improvement of bioavailability and regenerative medicine of ocular surface.
Axel Schambach is Acting Director of the Institute of Experimental Hematology and Professor for Gene modification of somatic cells at MHH (Hannover Medical School). Axel Schambach studied medicine in Hamburg, San Diego (UCSD), San Francisco (UCSF), Dallas, and Zürich. After his Dr. med. he moved to Hannover Medical School to join the Department of Experimental Hematology (Prof. Christopher Baum) and received his PhD in Molecular Medicine in 2005 from the Hannover Biomedical Research School. Since 2007 he is a group leader for hematopoietic gene and cell therapy at the Excellence cluster REBIRTH, a cluster with a strong focus in regenerative medicine. Since 2012 he is Associate Faculty and Visiting Scientist/Lecturer at the Boston Children’s Hospital at Harvard Medical School. His main interest is to understand the molecular pathophysiology of inborn and acquired diseases of the blood and immune system and to develop tailor-made gene therapy strategies for selected metabolic diseases and immunodeficiencies. Here, the generation of patient- and disease-specific induced pluripotent cells as an indefinite reservoir becomes increasingly important potentially creating the perspective of genetic correction and cell fate modification of stem and progenitor cells for combined cell and gene therapy in selected applications.
Dr. med. Tobias Schilling, born in 1973, studied medicine in Hannover from 1993 to 2003 with approbation as a physician and a doctoral thesis on the subject of "Tissue engineering of bioartificial heart valves" in 2004. After graduation, he first worked as a medical assistant in the Department of Cardiothoracic, Transplantation and Vascular Surgery at the MHH, before he took over the clinical management of this department in 2007. As a research assistant at the MHH, Dr. med. Schilling examines – in addition to questions regarding clinical management and health economics – the development of bioartificial heart muscle and aortic replacements, in close cooperation with the Leibniz University Hannover. As co-project leader "public relations" of the collaborative research centre 599, Dr. Schilling dealt both analytically and operationally with research communication. In 1998 he founded an internet company with a focus on internet marketing and eCommerce, in which he –is still active as a partner and advisor today. Dr. Schilling is the author of numerous publications and book chapters and has an experience of more than 150 scientific presentations and product presentations. As founder and CEO of a startup company and manager of a university clinic for heart surgery with an annual turnover of approximately 70 million Euros and about 500 employees, he can look back on countless successful but also non-successful negotiations.
Christoph Schindler is a clinical pharmacologist and heading the MHH CRC Core Facility at CRC Hannover. He studied medicine at the universities of Ulm, where he also received his Dr. med., and Toronto/Canada. In 2000 he moved to the Medical Faculty of the University Hospital Carl Gustav Carus at the Technical University Dresden and completed his speciality training in clinical pharmacology. In 2008 he finished his habilitation and received lecturer`s qualification. Since 2008 he was a group leader of the working group experimental cardiovascular clinical pharmacology (main interest: therapeutic manipulation of the renin-angiotensin-aldosterone-system and metabolism) and head of the phase I unit. In 2013 he was appointed as extraordinary Professor at the Medical Faculty of the Technical University Dresden. Since 2014 he is a full professor (W2) for clinical pharmacology – early clinical trials and drug research at Hannover Medical School.
Dr. med. Christian K. Schneider is Director of the National Institute for Biological Standards and Control (NIBSC), UK, a centre of the Medicines and Healthcare products Regulatory Agency (MHRA). Previous positions include Medical Head of Division Medicines Licensing and Availability at the Danish Medicines Agency, and Head of Division EU Co-operation/Microbiology at the Paul-Ehrlich-Institute, the German Federal Agency for Vaccines and Biomedicines. Previous Roles at the European Medicines Agency include Chair of the Committee for Advanced Therapies (CAT; 2009-2013), Chair of the Biosimilar Medicinal Products Working Party (BMWP; 2007-2016), and co-opted member of the Committee for Medicinal Products for Human Use for the area "Quality and safety (biological), with expertise in Advanced Therapies - Gene, Cell and Tissue Therapies" (CHMP; 2007-2011).
Professor Matthias P. Schönermark has been lecturing at the Hanover Medical School as a Professor of Management and teaching as a guest lecturer at various international universities and business schools since 2001.
The qualified Head and Neck Surgeon began his career in the field of strategy consulting at the Boston Consulting Group and as Associate Director at A.T. Kearney. In 2005 he founded the management consulting firm SKC together with Heike Kielhorn-Schönermark.
A key focus of his activities is the question of leadership as a strategic resource. Professsor Schönermark served on the board of directors at the NeuroLeadership Institute.
Michael Strätz studied at the Georg-August University in Göttingen where he completed his doctorate with the title “Horizontal Gene Transfer with Bacteria”. In 1992 he joined the Helmholtz Centre for Infection Research what was then called the Gesellschaft für Biotechnologische Forschung (GBF). There he formed a group for Environmental Genetics and was able to finance a significant part of it by acquiring third party funding. He was then able to expand his knowledge in this field when he took over as head of the group for third party funding, an interface between science and administration in 1998. He has now been head of the staff department Third party Funding and Controlling at HZI since 2003 and is responsible for the acquisition of both national and international funding, management of strategic projects and many sectors of technology transfer. In 2010 he became the authorized representative of the HZI business management.
Susanne Thiele studied biology at the Technical University of Braunschweig with the main focus on microbiology, biochemistry and botany. Her first professional station was at the Leibniz Institute for Plant Genetics and Cultivated Plant Breeding in Gatersleben. In 1999 she changed to the private sector and joined BIOBASE GmbH in Wolfenbüttel/Boston, an international developer and provider of scientific databases for the pharmaceutical and biotechnology industry, today part of QIAGEN. As Sales & Marketing Manager she was responsible for the support of international companies and took over corporate communications in 2006. Since 2007, Susanne Thiele has focused on science communication. She deals with the targeted communication of scientific topics to the general public at various research institutions and among other things has further qualified herself at the “Freie Journalisten Schule Berlin”. In 2007, she was spokeswoman for the anniversary year “Braunschweig – City of Science 2007”, hosted by the “Stifterverband für die Wissenschaft”. From 2012 to 2015, Susanne Thiele headed the press office at the Leibniz-Institute DSMZ-German Collection of Microorganisms and Cell Cultures in Braunschweig. Since the end of 2015, she has been Head of the Press and Communication Unit at the Helmholtz-Center for Infection Research (HZI). Susanne Thiele is responsible for the external and internal communication for the main campus in Braunschweig and the HZI locations in Hannover, Hamburg, Saarbrücken and Würzburg.
Since July 2008 Dr. Henning Voigt is research coordinator with focus on organizing (interdisciplinary) research activities of the Department of Otolaryngology at the MHH. He studied biology in Hannover and did his diploma thesis at the Department of Pharmacology, Toxicology and Pharmacy of the University of Veterinary Medicine Hannover (TiHo). After his doctoral thesis (Institute of Zoology, TiHo) he worked as contract researcher and gained experiences in the field of studies for pharmaceutical and biomedical industry under GLP conditions. Dr. Voigt is animal welfare officer of the Institute of AudioNeuroTechnology VIANNA (www.vianna.de) and contributed to the introduction of a quality management system according to ISO 9001 in the research field of CrossBIT (www.crossbit.eu). Moreover, as quality management representative he supports the introduction of a quality management system according to ISO 9001 at the Department of Otolaryngology which is planned for 2015.
Prof. Dr. Hermann Wätzig studied pharmacy at the Freie Universität Berlin from 1981 to 1985. PhD thesis 1989 about an HPLC topic, supervised by Prof. Dr. S. Ebel. From 1990 lecturer at the Institut für Pharmazie in Würzburg. Habilitation 1995. In 1999 appointment to a professorship in pharmaceutical chemistry at the Technical University of Braunschweig. Since 2001 chair of the division pharmaceutical analysis/quality control of the German Pharmaceutical Society. Editorial Board Member of the journal Electrophoresis. Scientific committee member of ISEAC. Main research interests: instrumental analysis, especially capillary and gel electrophoresis, chromatographic techniques and mass spectroscopy. Analysis from body fluids. Analysis of biopolymers. Proteome research. Quality control. Quality assurance. Drugs from biotechnical production. Ligand binding assays, Metallomics, Validation. Statistics. Surface analysis. High resolution microscopy (REM, AFM, etc.).
Dr. Weigt is biologist by training and majored in immunology and genetics. He moved to the pharmaceutically regulated field in 2000 while pursuing his dissertation on the production and quality control of cell therapy products according to GMP which were subsequently clinically tested. In continuation of this, he led a group focusing on the optimization of such products. In 2004, Dr. Weigt joined LipoNova AG. Initially, he developed and validated manufacturing processes and analytical methods for cancer immunotherapies and built the Quality part of the regulatory documentation in the course of a European marketing authorization application. In 2005, he was appointed head of quality control according to German drug law. From 2007 until 2015 Dr. Weigt was Project Manager for translational development of pharmaceuticals and later as Head of Quality Assurance with Vakzine Projekt Management GmbH. He was appointed Chief Operations Officer in 2013. In this function, he organizes and takes the responsibility for the company's daily operations. In October 2015 he returned to Fraunhofer ITEM, focusing on regulatory aspects in pharmaceutical development.
Following his graduation, Frank Wilmerstaedt was employed in different positions – product management, development, quality management, Regulatory Affairs – at various medical technology companies. In the course of his long-time work with a notified body he carried out conformity assessment procedures as auditor and expert for German and international medical device manufacturers.
Currently he is president of MDSS Consulting GmbH, a consulting company for economic operators in the field of medical technology. MDSS Consulting GmbH focuses primarily on topics relating to quality management, risk management and Regulatory Affairs associated with conformity assessment of medical devices. Regulatory support of new innovative medical devices, at stages ranging from research to development, production, certification and distribution to the patient, is his daily field of work.